Boston Scientific (NYSE:BSX) Price Target Cut to $87.00 by Analysts at Citigroup

Boston Scientific (NYSE:BSX) had its target price cut by stock analysts at Citigroup from $94.00 to $87.00 in a research note issued on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the medical equipment provider’s stock. Citigroup’s price target suggests a potential upside of 40.85% from the stock’s current price.

BSX has been the topic of a number of other research reports. TD Cowen reduced their price objective on Boston Scientific from $115.00 to $100.00 and set a “buy” rating on the stock in a research report on Monday, February 2nd. The Goldman Sachs Group reduced their price objective on Boston Scientific from $98.00 to $93.00 and set a “buy” rating on the stock in a research report on Friday, March 27th. Sanford C. Bernstein reiterated an “outperform” rating and set a $112.00 price objective on shares of Boston Scientific in a research report on Friday, February 6th. Raymond James Financial reiterated an “outperform” rating and set a $88.00 price objective (down from $97.00) on shares of Boston Scientific in a research report on Monday, March 30th. Finally, Stifel Nicolaus reduced their price objective on Boston Scientific from $110.00 to $90.00 and set a “buy” rating on the stock in a research report on Friday, March 20th. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, Boston Scientific has an average rating of “Moderate Buy” and an average target price of $104.05.

Boston Scientific Price Performance

Shares of NYSE BSX traded down $0.82 during midday trading on Tuesday, hitting $61.77. The stock had a trading volume of 9,001,235 shares, compared to its average volume of 15,807,031. The company has a market capitalization of $91.80 billion, a PE ratio of 31.87, a P/E/G ratio of 0.97 and a beta of 0.78. The stock has a 50 day simple moving average of $73.99 and a 200-day simple moving average of $89.01. Boston Scientific has a 1 year low of $60.90 and a 1 year high of $109.50. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.78 by $0.02. The business had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.29 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The business’s quarterly revenue was up 15.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, sell-side analysts expect that Boston Scientific will post 2.85 EPS for the current fiscal year.

Insider Transactions at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the sale, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Boston Scientific

Institutional investors have recently modified their holdings of the company. FWL Investment Management LLC acquired a new stake in shares of Boston Scientific in the second quarter valued at $26,000. Steph & Co. acquired a new stake in shares of Boston Scientific in the third quarter valued at $25,000. Murphy & Mullick Capital Management Corp grew its stake in shares of Boston Scientific by 200.0% in the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 170 shares in the last quarter. Financial Consulate Inc. acquired a new stake in shares of Boston Scientific in the third quarter valued at $25,000. Finally, Swiss RE Ltd. acquired a new stake in shares of Boston Scientific in the fourth quarter valued at $26,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Leerink reiterates an Outperform on BSX after the CHAMPION‑AF readout met primary safety and efficacy endpoints presented at ACC; analyst Mike Kratky kept a constructive view despite some data nuances, supporting the stock’s clinical credibility in electrophysiology. Read More.
• Positive Sentiment: Boston Scientific completed the acquisition of Valencia Technologies, a move that strengthens its position vs. Medtronic in an under‑penetrated market and could boost future EP/device revenue and competitive share. Read More.
• Neutral Sentiment: BSX appears in a roundup of Wall Street’s favorite long‑term stocks, which highlights bullish analyst price targets but also cautions about optimism in sell‑side forecasts. This may provide upside narrative but is not an immediate catalyst. Read More.
• Negative Sentiment: Multiple law firms and plaintiff‑side notices have announced securities‑fraud lawsuits and lead‑plaintiff deadlines (May 4, 2026) alleging disclosure issues—several filings/alerts from Gross Law Firm, Bernstein Liebhard, Rosen, Levi & Korsinsky, Glancy Prongay Wolke & Rotter, and Faruqi & Faruqi are circulating. The legal overhang raises potential settlement cost, management distraction, and uncertainty that can pressure the stock. Read More. Read More. Read More. Read More. Read More.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.